Mounjaro is one of the most talked-about molecules of recent years, and there is plenty of confusion around it. Some look for it "for weight loss," some as a diabetes drug, and some just heard the name in the news alongside Ozempic. So let us sort it out without the myths: what Mounjaro really is, which forms it comes in, its status in Ukraine, and how it differs from semaglutide.
The most important point first: Mounjaro is the brand name of the active substance tirzepatide, developed by the pharmaceutical company Eli Lilly. In other words, "Mounjaro" is the brand and tirzepatide is the molecule itself. It is a prescription medicine approved to treat type 2 diabetes, and it can be used only as prescribed by a doctor.
How tirzepatide works: a dual agonist
Tirzepatide is interesting because it is a dual agonist, it activates the receptors of two incretin hormones at once: GIP and GLP-1. For comparison, semaglutide (the active substance of Ozempic and Wegovy) acts on only one receptor, GLP-1. That is the main conceptual difference:
- GLP-1 boosts insulin production in response to glucose, slows gastric emptying, and reduces appetite;
- GIP, the second incretin pathway that tirzepatide engages additionally; the combination of two mechanisms is thought to give a different metabolic profile than "pure" GLP-1.
That is why tirzepatide is often called a "next-generation" drug relative to single agonists. Tirzepatide's efficacy in diabetes was studied in the SURPASS clinical trial program (phase 3), and a separate series of weight-management trials was run under the name SURMOUNT.
Mounjaro and Zepbound: one tirzepatide, two brands
Here lies another source of confusion. Eli Lilly releases tirzepatide under two different brand names for different indications:
| Brand | Indication | Company |
|---|---|---|
| Mounjaro | type 2 diabetes | Eli Lilly |
| Zepbound | chronic weight management (obesity) | Eli Lilly |
The molecule in them is the same, tirzepatide. The difference is the official indication the drug is registered for. So when people online write "Mounjaro for weight loss," they mean either a secondary metabolic effect or the Zepbound brand, and the specific decision about which drug fits which indication is always made by a doctor.
Forms and prescription status in Ukraine
Mounjaro comes in the form of pre-filled pen injectors (single-use injectors) for subcutaneous administration once a week. Different pens correspond to different doses, which is why a doctor selects the dose and regimen individually, with a gradual increase. There are no "universal protocols" for self-use here and there cannot be: this is a prescription drug.
In Ukraine, tirzepatide, like other members of this class, is dispensed by prescription. It is not a dietary supplement and not something you should prescribe to yourself from an internet article.
How much Mounjaro costs
The honest answer: a specific price cannot be named, and any "exact figures" in hryvnia should be treated skeptically. The cost of prescription drugs in this class is volatile; it depends on the dose, market availability, the distributor, and the exchange rate. So the only correct way to find the current price is to contact licensed pharmacies or check with a doctor at the time of prescribing. We deliberately do not publish made-up price lists.
Side effects: what to expect
The most common and best-documented class of tirzepatide side effects is gastrointestinal: nausea, vomiting, diarrhea, constipation, abdominal discomfort. They are usually most pronounced at the start and when the dose is increased. This is another reason selection and follow-up should be led by a doctor, not improvised.
What about research?
For a scientific and laboratory context, Longeva offers tirzepatide as a research substance with an independent COA (Certificate of Analysis, a lab certificate for the batch), a reagent for research, not the Mounjaro pharmaceutical brand and not a substitute for treatment. If you are interested in the molecule itself from the research side, see the tirzepatide page and the mechanism breakdown in the wiki. We put together a detailed comparison of tirzepatide with semaglutide and retatrutide in a separate article.
Summary. Mounjaro is the brand name of tirzepatide from Eli Lilly, a dual GIP/GLP-1 agonist registered for type 2 diabetes; for weight management the same tirzepatide is released under the Zepbound brand. These are prescription drugs in the form of weekly pen injectors, and their prescription, dose, and follow-up are determined by a doctor. The price is volatile, so check it at pharmacies, not in advertisements with "guaranteed" figures.
